SynthesisPloS one2024
Anti-Toxoplasma gondii IgG seroprevalence in the general population in Iran: A systematic review and meta-analysis, 2000-2023.
Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Seroprevalence of anti-Toxoplasma antibodies among hospitalized newborns and their mothers: associated factors and maternal awareness in a cross-sectional study in Yasuj, Iran.BMC pregnancy and childbirth · 2026Article
- Seroprevalence and Genotype Distribution ofHealth science reports · 2026Article
- Sero-evidence of Latent Toxoplasma Gondii Infection in Cancer Patients Before and After Chemotherapy, Northern Iran.Acta parasitologica · 2026Article
- Public Health Implications of Latent Toxoplasmosis and Its Association With Type 2 Diabetes: A Case-Control Study in Qazvin, North-Western Iran.Health science reports · 2026Article
- Investigating the prevalence of Toxoplasma gondii infection in Parkinson's disease patients and its association with disease severity: a case-control study.BMC infectious diseases · 2026Article
- Is there any association between latent Toxoplasma gondii seropositivity and hypothyroidism? A case-control registry-based study.BMC infectious diseases · 2025Article
- Prevalence of antibodies against rubella virus, cytomegalovirus, hepatitis b, and Toxoplasma gondii in women of reproductive age prior to conception in Iran.BMC infectious diseases · 2025Article
- Estimating the national seroprevalence ofEpidemiology and infection · 2025Article
- Epidemiological aspects and inflammatory cytokine profiles associated with Toxoplasma gondii infection in suicide attempters in Iran.BMC infectious diseases · 2025Article
- Pulmonary toxoplasmosis in a multiple myeloma patient: A Case report and literature review.International journal of molecular and cellular medicine · 2025Article
- Seroprevalence and risk factors associated with toxoplasmosis in nomadic, rural, and urban communities of northwestern Iran.Frontiers in public health · 2025Article
- Seroprevalence and Risk Factors forIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasmosis ranks among the most prevalent parasitic diseases globally. It seems that chronic toxoplasmosis is associated with several neuropsychiatric and other harmful effects in infected people, therefore, there is a need to investigate the prevalence of toxoplasmosis across various world regions. In this study, we conducted a meticulous meta-analysis to estimate the seroprevalence of anti-Toxoplasma gondii IgG antibodies within the general population in Iran (GPI). International and national scientific databases for studies published between January 1, 2000, and September 30, 2023, were searched. Observational studies reporting anti-T. gondii IgG seroprevalence in the GPI was selected/included. The data were synthesized using a random-effects model to calculate with a 95% confidence interval (95% CI) the national and regional anti-T. gondii IgG seroprevalence rates in Iran. Additionally, subgroup analyses were conducted to investigate the frequency of exposition to T. gondii in different socio-demographic, climatic, and geographical scenarios. From 18661 identified studies, 327 were included in the present meta-analysis, encompassing 122,882 individuals across the 31 Iranian provinces. The pooled nationwide anti-T. gondii IgG seroprevalence among the GPI was determined to be 32.9% (95% CI: 30.9-35.1%). The highest anti-T. gondii IgG seroprevalence was observed in Mazandaran province (North of Iran) (61%), whereas the lowest was in Semnan province (12.5%).Anti-T. gondii IgG seroprevalence demonstrated a higher occurrence in provinces characterized by moderate temperatures of 16-21°C, high relative humidity, and annual precipitation. Additionally, a higher anti-T. gondii IgG seroprevalence was identified among individuals with a habit of consumption of undercooked meat, raw fruits or vegetables, and untreated water. Moreover, those reporting direct contact with cats, possessing a lower level of education, residing in rural areas, being engaged in farming occupations, or playing the role of housewives exhibited higher anti-T. gondii IgG seroprevalence figures.The anti-T. gondii IgG seroprevalence within GPI closely aligns with the estimated worldwide average exposition rates. This underscores the imperative for public health policymakers to prioritize educational efforts regarding toxoplasmosis transmission pathways and its link to harmful effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.